GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Asset Turnover

Aprinoia Therapeutics (Aprinoia Therapeutics) Asset Turnover : 0.90 (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Aprinoia Therapeutics's Revenue for the six months ended in Jun. 2023 was $9.03 Mil. Aprinoia Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $10.06 Mil. Therefore, Aprinoia Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 was 0.90.

Asset Turnover is linked to ROE % through Du Pont Formula. Aprinoia Therapeutics's annualized ROE % for the quarter that ended in Jun. 2023 was 18.26%. It is also linked to ROA % through Du Pont Formula. Aprinoia Therapeutics's annualized ROA % for the quarter that ended in Jun. 2023 was -142.85%.


Aprinoia Therapeutics Asset Turnover Historical Data

The historical data trend for Aprinoia Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Asset Turnover Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Asset Turnover
0.04 0.04

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Asset Turnover - 0.02 0.02 0.90

Competitive Comparison of Aprinoia Therapeutics's Asset Turnover

For the Biotechnology subindustry, Aprinoia Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Asset Turnover falls into.



Aprinoia Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Aprinoia Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0.394/( (12.766+5.643)/ 2 )
=0.394/9.2045
=0.04

Aprinoia Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=9.034/( (5.643+14.476)/ 2 )
=9.034/10.0595
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Aprinoia Therapeutics  (NAS:APRI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Aprinoia Therapeutics's annulized ROE % for the quarter that ended in Jun. 2023 is

ROE %**(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-14.37/-78.691
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.37 / 18.068)*(18.068 / 10.0595)*(10.0595/ -78.691)
=Net Margin %*Asset Turnover*Equity Multiplier
=-79.53 %*1.7961*-0.1278
=ROA %*Equity Multiplier
=-142.85 %*-0.1278
=18.26 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Aprinoia Therapeutics's annulized ROA % for the quarter that ended in Jun. 2023 is

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-14.37/10.0595
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-14.37 / 18.068)*(18.068 / 10.0595)
=Net Margin %*Asset Turnover
=-79.53 %*1.7961
=-142.85 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Aprinoia Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines